ORYZON to give updates on corporate progress in March and April

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March and April.

Oryzon will participate at the virtual event Bio-Europe Spring 2022, which will be held on March 28-31. Dr. Carlos Buesa, Oryzon’s CEO, and Dr. Saikat Nandi, Oryzon’s Global Chief Business Officer, will hold one-to-one meetings with pharmaceutical companies and global investors. https://informaconnect.com/bioeurope-spring/

Oryzon has been invited to participate at the Kempen Life Sciences Conference, which will be held on April 20-21 in Amsterdam, the Netherlands. Dr. Buesa will hold one-to-one meetings with pharmaceutical companies and global investors. https://www.kempen.com/en/securities/events/upcoming-events-securities

Dr. Buesa and Dr. Enric Rello, Oryzon’s CFO, will attend the Asebio Investor Day, which will be held on April 27-28 in Madrid, Spain. Dr. Buesa and Dr. Rello will hold one-to-one meetings with national investors. https://www.asebio.com/actualidad/agenda/asebio-investor-day-2022

More information in the file attached